Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)
Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans, often demonstrating resistance to multimodal therapeutic approaches. The median survival of ATC patients after initial diagnosis was reported to be
Gespeichert in:
| Veröffentlicht in: | BMC cancer 2015-06, Vol.15 (1), p.475-475, Article 475 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 475 |
|---|---|
| container_issue | 1 |
| container_start_page | 475 |
| container_title | BMC cancer |
| container_volume | 15 |
| creator | Onoda, Naoyoshi Sugitani, Iwao Higashiyama, Takuya Hara, Hisato Ito, Ken-ichi Kammori, Makoto Sugino, Kiminori Suzuki, Shinichi Toda, Kazuhisa Yoshida, Akira Miyauchi, Akira |
| description | Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans, often demonstrating resistance to multimodal therapeutic approaches. The median survival of ATC patients after initial diagnosis was reported to be |
| doi_str_mv | 10.1186/s12885-015-1490-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4474467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541402996</galeid><sourcerecordid>A541402996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c601t-b10c7cd1b662be7d981d20e0374d299bdf063809e0683bb77975da9f1ac1c5ec3</originalsourceid><addsrcrecordid>eNptkt9q2zAUxs3YWLtuD7CbIRiM9sKN5CiyfFMIYX86CitbBrsTsnQUa1Msz5Kb-tH2dpNJVxIYupCO9Ps-jg5flr0m-JIQzmaBFJwvckwWOaEVzvmT7JTQkuQFxeXTg_NJ9iKEnxiTkmP-PDspGK4Ip-w0-7PyrYIuItlqpCHYTYu8QRK1Mlrf7qwG1PU-dKCivQNkQAZbW2fjOANjrJJqnAVpII4oxEGPk3oH8MuNqJMqcfIeHDK-T2W00MaAdjY2U9V45zfJwSVW-dbYfgs6NSI7J0O0CsVm7L3VSMnUY4_Ol-vV6nN-u_6R3xYXL7NnRroArx72s-z7h_fr1af85svH69XyJlcMk5jXBKtSaVIzVtRQ6ooTXWDA85LqoqpqbTCbc1wBZnxe12VZlQstK0OkImoBan6WXe19u6FO_an0hV460fV2K_tReGnF8UtrG7Hxd4LSklJWJoPzB4Pe_x4gRLG1QYFzsgU_BEFYhRnlVUkS-naPbqQDYVvjk6OacLFcUEJx6pgl6vI_VFoatjYNEoxN90eCiyNBYiLcx40cQhDX374es-8O2Aaki03wbpjSEI5BsgdVikfowTyOhGAxxVPs4ylSPMUUT8GT5s3hLB8V__I4_wuVWeLA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1690648971</pqid></control><display><type>article</type><title>Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Onoda, Naoyoshi ; Sugitani, Iwao ; Higashiyama, Takuya ; Hara, Hisato ; Ito, Ken-ichi ; Kammori, Makoto ; Sugino, Kiminori ; Suzuki, Shinichi ; Toda, Kazuhisa ; Yoshida, Akira ; Miyauchi, Akira</creator><creatorcontrib>Onoda, Naoyoshi ; Sugitani, Iwao ; Higashiyama, Takuya ; Hara, Hisato ; Ito, Ken-ichi ; Kammori, Makoto ; Sugino, Kiminori ; Suzuki, Shinichi ; Toda, Kazuhisa ; Yoshida, Akira ; Miyauchi, Akira</creatorcontrib><description>Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans, often demonstrating resistance to multimodal therapeutic approaches. The median survival of ATC patients after initial diagnosis was reported to be <6 months due to the rapid progression of disease by dissemination and/or invasion. There have been several reports describing possible effective chemotherapies, but these studies might be biased by the nature of retrospective accumulations of clinical experiences, and thus reliable data concerning the efficacies of the treatment efforts are required.
In 2009, we established the research organization Anaplastic Carcinoma Research Consortium Japan (ATCCJ) to investigate this highly malignant disease. Using this nationwide organization, we conducted a prospective clinical study to investigate the feasibility, safeness, and efficacy of chemotherapy with weekly paclitaxel for ATC patients. This trial is registered on the clinical trials site of the University Hospital Medical Information Network Clinical Trials Registry Web site (UMIN000008574). The study was started in 2012, and enrollment was closed in March 2014 after accumulating 71 patients from 28 registered institutes. The follow-up data will be available in April 2015.
Important information concerning the management of this disease is expected to be revealed by this study. The concept and design of the study are described herein.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-015-1490-8</identifier><identifier>PMID: 26091846</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Cancer ; Care and treatment ; Chemotherapy ; Development and progression ; Drug therapy ; Feasibility Studies ; Female ; Health aspects ; Humans ; Japan ; Male ; Middle Aged ; Neoplasm Staging ; Paclitaxel - administration & dosage ; Prognosis ; Study Protocol ; Thyroid cancer ; Thyroid Carcinoma, Anaplastic - drug therapy ; Thyroid Carcinoma, Anaplastic - epidemiology ; Thyroid Carcinoma, Anaplastic - pathology ; Treatment Outcome</subject><ispartof>BMC cancer, 2015-06, Vol.15 (1), p.475-475, Article 475</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>Onoda et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c601t-b10c7cd1b662be7d981d20e0374d299bdf063809e0683bb77975da9f1ac1c5ec3</citedby><cites>FETCH-LOGICAL-c601t-b10c7cd1b662be7d981d20e0374d299bdf063809e0683bb77975da9f1ac1c5ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474467/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474467/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26091846$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onoda, Naoyoshi</creatorcontrib><creatorcontrib>Sugitani, Iwao</creatorcontrib><creatorcontrib>Higashiyama, Takuya</creatorcontrib><creatorcontrib>Hara, Hisato</creatorcontrib><creatorcontrib>Ito, Ken-ichi</creatorcontrib><creatorcontrib>Kammori, Makoto</creatorcontrib><creatorcontrib>Sugino, Kiminori</creatorcontrib><creatorcontrib>Suzuki, Shinichi</creatorcontrib><creatorcontrib>Toda, Kazuhisa</creatorcontrib><creatorcontrib>Yoshida, Akira</creatorcontrib><creatorcontrib>Miyauchi, Akira</creatorcontrib><title>Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans, often demonstrating resistance to multimodal therapeutic approaches. The median survival of ATC patients after initial diagnosis was reported to be <6 months due to the rapid progression of disease by dissemination and/or invasion. There have been several reports describing possible effective chemotherapies, but these studies might be biased by the nature of retrospective accumulations of clinical experiences, and thus reliable data concerning the efficacies of the treatment efforts are required.
In 2009, we established the research organization Anaplastic Carcinoma Research Consortium Japan (ATCCJ) to investigate this highly malignant disease. Using this nationwide organization, we conducted a prospective clinical study to investigate the feasibility, safeness, and efficacy of chemotherapy with weekly paclitaxel for ATC patients. This trial is registered on the clinical trials site of the University Hospital Medical Information Network Clinical Trials Registry Web site (UMIN000008574). The study was started in 2012, and enrollment was closed in March 2014 after accumulating 71 patients from 28 registered institutes. The follow-up data will be available in April 2015.
Important information concerning the management of this disease is expected to be revealed by this study. The concept and design of the study are described herein.</description><subject>Adult</subject><subject>Aged</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Japan</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Paclitaxel - administration & dosage</subject><subject>Prognosis</subject><subject>Study Protocol</subject><subject>Thyroid cancer</subject><subject>Thyroid Carcinoma, Anaplastic - drug therapy</subject><subject>Thyroid Carcinoma, Anaplastic - epidemiology</subject><subject>Thyroid Carcinoma, Anaplastic - pathology</subject><subject>Treatment Outcome</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkt9q2zAUxs3YWLtuD7CbIRiM9sKN5CiyfFMIYX86CitbBrsTsnQUa1Msz5Kb-tH2dpNJVxIYupCO9Ps-jg5flr0m-JIQzmaBFJwvckwWOaEVzvmT7JTQkuQFxeXTg_NJ9iKEnxiTkmP-PDspGK4Ip-w0-7PyrYIuItlqpCHYTYu8QRK1Mlrf7qwG1PU-dKCivQNkQAZbW2fjOANjrJJqnAVpII4oxEGPk3oH8MuNqJMqcfIeHDK-T2W00MaAdjY2U9V45zfJwSVW-dbYfgs6NSI7J0O0CsVm7L3VSMnUY4_Ol-vV6nN-u_6R3xYXL7NnRroArx72s-z7h_fr1af85svH69XyJlcMk5jXBKtSaVIzVtRQ6ooTXWDA85LqoqpqbTCbc1wBZnxe12VZlQstK0OkImoBan6WXe19u6FO_an0hV460fV2K_tReGnF8UtrG7Hxd4LSklJWJoPzB4Pe_x4gRLG1QYFzsgU_BEFYhRnlVUkS-naPbqQDYVvjk6OacLFcUEJx6pgl6vI_VFoatjYNEoxN90eCiyNBYiLcx40cQhDX374es-8O2Aaki03wbpjSEI5BsgdVikfowTyOhGAxxVPs4ylSPMUUT8GT5s3hLB8V__I4_wuVWeLA</recordid><startdate>20150620</startdate><enddate>20150620</enddate><creator>Onoda, Naoyoshi</creator><creator>Sugitani, Iwao</creator><creator>Higashiyama, Takuya</creator><creator>Hara, Hisato</creator><creator>Ito, Ken-ichi</creator><creator>Kammori, Makoto</creator><creator>Sugino, Kiminori</creator><creator>Suzuki, Shinichi</creator><creator>Toda, Kazuhisa</creator><creator>Yoshida, Akira</creator><creator>Miyauchi, Akira</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150620</creationdate><title>Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)</title><author>Onoda, Naoyoshi ; Sugitani, Iwao ; Higashiyama, Takuya ; Hara, Hisato ; Ito, Ken-ichi ; Kammori, Makoto ; Sugino, Kiminori ; Suzuki, Shinichi ; Toda, Kazuhisa ; Yoshida, Akira ; Miyauchi, Akira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c601t-b10c7cd1b662be7d981d20e0374d299bdf063809e0683bb77975da9f1ac1c5ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Japan</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Paclitaxel - administration & dosage</topic><topic>Prognosis</topic><topic>Study Protocol</topic><topic>Thyroid cancer</topic><topic>Thyroid Carcinoma, Anaplastic - drug therapy</topic><topic>Thyroid Carcinoma, Anaplastic - epidemiology</topic><topic>Thyroid Carcinoma, Anaplastic - pathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onoda, Naoyoshi</creatorcontrib><creatorcontrib>Sugitani, Iwao</creatorcontrib><creatorcontrib>Higashiyama, Takuya</creatorcontrib><creatorcontrib>Hara, Hisato</creatorcontrib><creatorcontrib>Ito, Ken-ichi</creatorcontrib><creatorcontrib>Kammori, Makoto</creatorcontrib><creatorcontrib>Sugino, Kiminori</creatorcontrib><creatorcontrib>Suzuki, Shinichi</creatorcontrib><creatorcontrib>Toda, Kazuhisa</creatorcontrib><creatorcontrib>Yoshida, Akira</creatorcontrib><creatorcontrib>Miyauchi, Akira</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onoda, Naoyoshi</au><au>Sugitani, Iwao</au><au>Higashiyama, Takuya</au><au>Hara, Hisato</au><au>Ito, Ken-ichi</au><au>Kammori, Makoto</au><au>Sugino, Kiminori</au><au>Suzuki, Shinichi</au><au>Toda, Kazuhisa</au><au>Yoshida, Akira</au><au>Miyauchi, Akira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2015-06-20</date><risdate>2015</risdate><volume>15</volume><issue>1</issue><spage>475</spage><epage>475</epage><pages>475-475</pages><artnum>475</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans, often demonstrating resistance to multimodal therapeutic approaches. The median survival of ATC patients after initial diagnosis was reported to be <6 months due to the rapid progression of disease by dissemination and/or invasion. There have been several reports describing possible effective chemotherapies, but these studies might be biased by the nature of retrospective accumulations of clinical experiences, and thus reliable data concerning the efficacies of the treatment efforts are required.
In 2009, we established the research organization Anaplastic Carcinoma Research Consortium Japan (ATCCJ) to investigate this highly malignant disease. Using this nationwide organization, we conducted a prospective clinical study to investigate the feasibility, safeness, and efficacy of chemotherapy with weekly paclitaxel for ATC patients. This trial is registered on the clinical trials site of the University Hospital Medical Information Network Clinical Trials Registry Web site (UMIN000008574). The study was started in 2012, and enrollment was closed in March 2014 after accumulating 71 patients from 28 registered institutes. The follow-up data will be available in April 2015.
Important information concerning the management of this disease is expected to be revealed by this study. The concept and design of the study are described herein.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>26091846</pmid><doi>10.1186/s12885-015-1490-8</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2015-06, Vol.15 (1), p.475-475, Article 475 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4474467 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Aged Cancer Care and treatment Chemotherapy Development and progression Drug therapy Feasibility Studies Female Health aspects Humans Japan Male Middle Aged Neoplasm Staging Paclitaxel - administration & dosage Prognosis Study Protocol Thyroid cancer Thyroid Carcinoma, Anaplastic - drug therapy Thyroid Carcinoma, Anaplastic - epidemiology Thyroid Carcinoma, Anaplastic - pathology Treatment Outcome |
| title | Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A15%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Concept%20and%20design%20of%20a%20nationwide%20prospective%20feasibility/efficacy/safety%20study%20of%20weekly%20paclitaxel%20for%20patients%20with%20pathologically%20confirmed%20anaplastic%20thyroid%20cancer%20(ATCCJ-PTX-P2)&rft.jtitle=BMC%20cancer&rft.au=Onoda,%20Naoyoshi&rft.date=2015-06-20&rft.volume=15&rft.issue=1&rft.spage=475&rft.epage=475&rft.pages=475-475&rft.artnum=475&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-015-1490-8&rft_dat=%3Cgale_pubme%3EA541402996%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1690648971&rft_id=info:pmid/26091846&rft_galeid=A541402996&rfr_iscdi=true |